Clinical Trials Logo

Clinical Trial Summary

Feeding intolerance is a common problem in the NICU. Feeding intolerance complicates the hospitalization, lengthens the hospital stay, and adds substantially to the cost of care. We developed a method aimed at treating intestinal villous atrophy. We accomplished preclinical testing of the product, and four Phase I clinical trials, including two at McKay-Dee Hospital in 2004. Our preparation is a sterile, isotonic, solution that simulates human amniotic fluid in electrolyte composition, albumin concentration, and two enterocyte growth factors that are present in human amniotic fluid; erythropoietin and granulocyte colony-stimulating factor. We termed the product SAFEstart, using the acronym Simulated Amniotic Fluid for Enteral administration. This trial on the efficacy and safety of SAFEstart administration as a treatment for neonates who have feeding intolerance.

Hypothesis is that infants with feeding intolerance, randomized to the SAFEstart will have a greater enteral calories per kilogram per day for the seven days following conclusion of the SAFEstart administration.


Clinical Trial Description

Feeding intolerance is relatively common in the NICU. It can manifest as emesis, diarrhea, increased abdominal girth (bloating), or in the most severe cases as necrotizing enterocolitis. Feeding intolerance complicates the hospitalization, lengthens the hospital stay, and adds substantially to the cost of care. Feeding intolerance likely has many causes. One cause that may be particularly common in the NICU is atrophy of the intestinal mucosa, which occurs during enteral fasting (when a patient is NPO). Significant intestinal villous atrophy occurs after being NPO for even 1-2 days; even if parenteral nutrition is adequate.

We developed a method aimed at preventing intestinal villous atrophy of neonates who are NPO. We accomplished preclinical testing of the product, and we completed two Phase I clinical trials involving 60 neonates. Our preparation is a sterile, isotonic, solution that simulates human amniotic fluid in electrolyte composition, albumin concentration, and two enterocyte growth factors that are present in human amniotic fluid; erythropoietin and granulocyte colony-stimulating factor. We termed the product SAFEstart, using the acronym Simulated Amniotic Fluid for Enteral administration.

SAFEstart has been tested in neonates who have never been fed, as a means of preventing villous mucosal atrophy. However, it has not yet been tested in neonates who develop feeding intolerance after several days or weeks of life. When feeding intolerance develops in such patients, the current treatments include changing formulas, continuous feeding, but does not include using SAFEstart.

It is possible that SAFEstart administration, 2.5 mL/kg enterally every three hours as we have previously done with preterm neonates beginning on the first day of life, would provide benefit to these older neonates with acquired feeding intolerance. If such infants have mucosal atrophy as part of their feeding problem, the growth factors in SAFEstart might indeed result in improved feeding tolerance.

We propose a Phase II exploratory trial among 20 neonates in the McKay-Dee NICU who develop the problem of feeding intolerance. Specifically, we propose that when feeding intolerance is diagnosed, 20 mL/kg/day of SAFEstart will be administered (every three hour gavage or nipple feedings) and that this will be continued for a period of up to one week, in an attempt to resolve the feeding intolerance. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00331201
Study type Interventional
Source Intermountain Health Care, Inc.
Contact
Status Completed
Phase Phase 2
Start date July 2005
Completion date April 2006

See also
  Status Clinical Trial Phase
Terminated NCT03320785 - Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation
Completed NCT00997854 - Preterm Neonatal Feeding Protocol Comparing Feed Administration Time N/A
Not yet recruiting NCT02534090 - Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy N/A
Completed NCT02980250 - Multi-Center Study of Different Doses Domperidone in Feeding Intolerance Phase 4
Recruiting NCT02149407 - Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants N/A
Completed NCT03822104 - Bovine Colostrum as a Human Milk Fortifier for Preterm Infants N/A
Recruiting NCT05347706 - Protocol for Feeding Intolerance in Preterm Infants N/A
Recruiting NCT02598375 - Evaluation of Status of Early Reached Target Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children N/A
Terminated NCT02028156 - Feeding Intolerance in Formula-Fed Infants N/A
Completed NCT01191112 - Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population Phase 3
Completed NCT01441427 - Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial Phase 1/Phase 2
Completed NCT02054091 - Feeding Bovine Colostrum to Preterm Infants N/A
Completed NCT01987154 - Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula N/A
Recruiting NCT00450697 - Feeding Tolerance in Preterm Infants N/A
Completed NCT03537365 - Bovine Colostrum as a Fortifier Added to Human Milk for Preterm Infants N/A
Completed NCT04304807 - Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants Phase 4
Not yet recruiting NCT00550069 - Observational Study of Infants Born at 34 to 37 Weeks of Gestation Until the Age of 1 Year N/A
Not yet recruiting NCT04950738 - The Effectiveness of Acupuncture for Complications in Critically Ill Patients N/A